Pacira BioSciences, Inc. Receives Analysts' Average Target Price of $22.78

Pacira BioSciences, Inc. (NASDAQ:PCRX) has received an average rating of "Hold" from the nine firms currently analyzing its stock, according to reports from Marketbeat. Among these analysts, one has issued a sell rating, five have maintained a hold rating, and three have issued buy ratings. The collective average price target set by brokers covering the stock in the past year stands at $22.78.

Several research analysts have shared their insights on Pacira BioSciences. HC Wainwright reaffirmed a "buy" rating and set a price target of $39.00 for the shares in a research note dated December 4th. Meanwhile, Needham & Company LLC increased their target price for the company from $22.00 to $30.00, continuing to endorse a "buy" rating in a note issued on January 13th. On the other hand, Barclays reduced their price estimate from $25.00 to $17.00 while assigning an "equal weight" rating in their research on November 12th. Royal Bank of Canada also maintained a "sector perform" rating, issuing a target price of $18.00 in a note on January 14th. Additionally, Truist Financial upgraded the stock from a "sell" to a "hold" rating and raised their target price from $8.00 to $25.00 in their report released on January 30th.

Market Performance of Pacira BioSciences

As of Thursday morning, Pacira BioSciences traded at $25.44, marking a decline of 4.1%. The company has a debt-to-equity ratio of 0.51, with a quick ratio of 1.89 and a current ratio of 2.25. Its market capitalization is approximately $1.17 billion, with a PE ratio of -12.53 and a beta of 0.80. Over the past year, the company's stock has seen a low of $11.16 and a high of $31.67. The fifty-day moving average stands at $22.00, while the two-hundred-day moving average is at $18.15.

Institutional Holdings in Pacira BioSciences

Recent changes in institutional holdings indicate significant shifts in stock ownership. Pacer Advisors Inc. increased their stake in Pacira BioSciences by 129.4% during the third quarter, having acquired an additional 2,799,434 shares, bringing their total to 4,962,221 shares valued at $74,681,000. Similarly, State Street Corp raised their holdings by 5.8%, now owning 2,014,012 shares worth $30,311,000 after purchasing 110,162 shares in the previous quarter. Other institutional investors, including Renaissance Technologies LLC and Geode Capital Management LLC, have also boosted their investments in the company during the last two quarters. Notably, hedge funds and other institutions own approximately 99.73% of Pacira BioSciences' stock.

About Pacira BioSciences

Pacira BioSciences, Inc. is a holding company focused on providing non-opioid pain management and regenerative health solutions designed to enhance patient experiences along the neural pain pathway. The company’s product portfolio includes EXPAREL, iovera, and DepoFoam. Founded in December 2006, Pacira is headquartered in Tampa, Florida.

Pacira, BioSciences, Stock